Skip to main content

Advertisement

SpringerLink
Log in

Pemetrexed for primary central nervous system lymphoma in the elderly

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Objective

The aim of this study was to evaluate the efficacy and safety of a consecutive series of elderly patients with primary central nervous system lymphoma (PCNSL) treated with single-agent pemetrexed without radiotherapy or intrathecal chemotherapy.

Methods

Twelve histologically confirmed newly diagnosed PCNSL patients older than 65 years were studied between 2008 and 2013. An induction chemotherapy was initially given (pemetrexed 600 mg/m2 on day 1, every 3 weeks). Patients achieving a complete, partial response or stable disease proceeded to a maintenance phase (up to 6 cycles). Patients with progressive/recurrent disease (PD) were treated with whole brain radiotherapy on an individual basis.

Results

Four patients presented complete response, six patients showed partial response and two patients presented progressive disease. The median progression-free survival (PFS) was 9.0 months [95 % confidence interval (CI) 2.0–45.3] and the median overall survival was 19.5 months (95 % CI 5.0–45.3). Adverse events included leukocytopenia, anemia, fatigue, rash and vomiting. No neurotoxicity or treatment-related death was observed. The estimated 1-year and 2-year survival rate was 66.7 and 41.7 %, respectively.

Conclusions

Our efficacy results demonstrate that the single-agent pemetrexed was feasible, active and well tolerated in elderly patients with PCNSL. Furthermore, this single-agent regimen results in higher response rates and less toxicity comparable with other chemotherapy or radiotherapy regimens. Prospectively, controlled studies are warranted to confirm such results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Olson JE, Janney CA, Rao RD, Cerhan JR, Kurtin PJ, Schiff D, et al. The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer. 2002;95:1504–10.

    Article  PubMed  Google Scholar 

  2. Ferreri AJ, Reni M, Pasini F, Calderoni A, Tirelli U, Pivnik A, et al. A multicenter study of treatment of primary CNS lymphoma. Neurology. 2002;58:1513–20.

    Article  CAS  PubMed  Google Scholar 

  3. Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003;21:266–72.

    Article  PubMed  Google Scholar 

  4. Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol. 2006;24:5711–5.

    Article  PubMed  Google Scholar 

  5. CBTRUS. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004–2006. Hinsdale, IL: Central Brain Tumor Registry of the United States. 2010. www.cbtrus.org.

  6. Hoang-Xuan K, Taillandier L, Chinot O, Soubeyran P, Bogdhan U, Hildebrand J, et al. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol. 2003;21:2726–31.

    Article  CAS  PubMed  Google Scholar 

  7. Jahnke K, Korfel A, Martus P, Weller M, Herrlinger U, Schmittel A, et al. High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann Oncol. 2005;16:445–9.

    Article  CAS  PubMed  Google Scholar 

  8. Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol. 2000;18:3144–50.

    CAS  PubMed  Google Scholar 

  9. Omuro AM, Taillandier L, Chinot O, Carnin C, Barrie M, Hoang-Xuan K. Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J Neurooncol. 2007;85:207–11.

    Article  CAS  PubMed  Google Scholar 

  10. Omuro AM, Ben-Porat LS, Panageas KS, Kim AK, Correa DD, Yahalom J, et al. Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol. 2005;62:1595–600.

    Article  PubMed  Google Scholar 

  11. Kasenda B, Rehberg M, Thurmann P, Franzem M, Veelken H, Fritsch K, et al. The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients. Ann Hematol. 2012;91:1257–64.

    Article  CAS  PubMed  Google Scholar 

  12. Zhu JJ, Gerstner ER, Engler DA, Mrugala MM, Nugent W, Nierenberg K, et al. High-dose methotrexate for elderly patients with primary CNS lymphoma. Neuro Oncol. 2009;11:211–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997;57:1116–23.

    CAS  PubMed  Google Scholar 

  14. Raizer JJ, Rademaker A, Evens AM, Rice L, Schwartz M, Chandler JP, et al. Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma. Cancer. 2012;118:3743–8.

    Article  CAS  PubMed  Google Scholar 

  15. Fritsch K, Kasenda B, Hader C, Nikkhah G, Prinz M, Haug V, et al. Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly. Ann Oncol. 2011;22:2080–5.

    Article  CAS  PubMed  Google Scholar 

  16. Panageas KS, Elkin EB, Ben-Porat L, Deangelis LM, Abrey LE. Patterns of treatment in older adults with primary central nervous system lymphoma. Cancer. 2007;110:1338–44.

    Article  PubMed  Google Scholar 

  17. Nelson DF, Martz KL, Bonner H, Nelson JS, Newall J, Kerman HD, et al. Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys. 1992;23:9–17.

    Article  CAS  PubMed  Google Scholar 

  18. Illerhaus G, Marks R, Muller F, Ihorst G, Feuerhake F, Deckert M, et al. High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. Ann Oncol. 2009;20:319–25.

    Article  CAS  PubMed  Google Scholar 

  19. Ng S, Rosenthal MA, Ashley D, Cher L. High-dose methotrexate for primary CNS lymphoma in the elderly. Neuro Oncol. 2000;2:40–4.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Roth P, Martus P, Kiewe P, Mohle R, Klasen H, Rauch M, et al. Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial. Neurology. 2012;79:890–6.

    Article  PubMed  Google Scholar 

  21. Welch MR, Omuro A, Deangelis LM. Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center. Neuro Oncol. 2012;14:1304–11.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Kurzwelly D, Glas M, Roth P, Weimann E, Lohner H, Waha A, et al. Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. J Neurooncol. 2010;97:389–92.

    Article  CAS  PubMed  Google Scholar 

  23. Olivier G, Clavert A, Lacotte-Thierry L, Gardembas M, Escoffre-Barbe M, Brion A, et al. A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trial. Am J Hematol. 2014;89:1024–9.

    Article  CAS  PubMed  Google Scholar 

  24. Lee SY, Okoshi Y, Kurita N, Seki M, Yokoyama Y, Maie K, et al. Prognosis factors in Japanese elderly patients with primary central nervous system lymphoma treated with a nonradiation, intermediate-dose methotrexate-containing regimen. Oncol Res Treat. 2014;37:378–83.

    Article  CAS  PubMed  Google Scholar 

  25. Ney DE, Reiner AS, Panageas KS, Brown HS, DeAngelis LM, Abrey LE. Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center experience. Cancer. 2010;116:4605–12.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Department of Oncology, Shandong Cancer Hospital and Institute, Shandong University, No. 440 of Jiyan Road, Jinan, 250117, Shandong, People’s Republic of China

    S. Han, B. Liu & J. Yu

  2. The Department of Oncology, Jiaozhou Central Hospital of Qingdao, No. 29 of Xuzhou Road, Jiaozhou, Qingdao, 266300, Shandong, People’s Republic of China

    M. Wang

Authors
  1. S. Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Yu.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Han, S., Wang, M., Liu, B. et al. Pemetrexed for primary central nervous system lymphoma in the elderly. Clin Transl Oncol 18, 138–143 (2016). https://doi.org/10.1007/s12094-015-1345-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-015-1345-4

Keywords

Search

Navigation